FDA Approves Camizestrant, Intercepting Breast Cancer Resistance Before Tumor Growth

FDA approves AstraZeneca breast cancer drug

Today's biotech news covers Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs, etc.

AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

FDA Approves Camizestrant, Intercepting Breast Cancer Resistance Before Tumor Growth

FDA approves AstraZeneca’s Etcamah (camizestrant), the first ctDNA-guided therapy to intercept breast cancer resistance before progression.

FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote

AstraZeneca clinched an FDA accelerated approval for its oral SERD in certain breast cancer patients Friday, even after a negative vote from the agency’s advisory committee in April. Camizestrant, with the brand ...